Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.61 |
| ▸ | CDK1 | P06493 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | CDK7 | P50613 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.61 |
| ▸ | CCND1 | P24385 | 8/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.59 |
| ▸ | CDK9 | P50750 | 2/20 | 0.59 |
| ▸ | CCND2 | P30279 | 4/20 | 0.59 |
| ▸ | CCND3 | P30281 | 4/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.59 |
| ▸ | CDK2 | P24941 | 4/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616460 | 0.88 | CDK4 (0.58) | CDK4CDK1CCND1CCND2CCND3 | |
| SCHEMBL13616186 | 0.88 | CDK4 (0.68) | CDK4CDK1CDK7CCND1CCNT1 | |
| SCHEMBL13616301 | 0.84 | CDK4 (0.62) | CDK4CDK1CCND1CCNT1CDK9 | |
| SCHEMBL17396455 | 0.83 | CDK4 (0.61) | CDK4CDK1SRCKDRPDGFRB | |
| SCHEMBL11976974 | 0.82 | RPS6KA6 (0.59) | CDK4CDK1SRCKDRPDGFRB | |
| SCHEMBL13616293 | 0.82 | CDK4 (0.60) | CDK4CDK1SRCKDRPDGFRB | |
| SCHEMBL13616280 | 0.81 | ALK (0.56) | CDK4CCND1CCND2CCND3CCNE1 | |
| SCHEMBL7715488 | 0.81 | RPS6KA6 (0.64) | CDK4CDK1SRCKDRPDGFRB | |
| SCHEMBL7714435 | 0.80 | RPS6KA6 (0.63) | CDK4CDK1SRCKDRPDGFRB | |
| SCHEMBL25046172 | 0.79 | CDK4 (0.59) | CDK4CDK1SRCKDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CDK1 44/4885SRC 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.